AAZ-A-154
|  | |
| Identifiers | |
|---|---|
| IUPAC name 
 | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C14H20N2O | 
| Molar mass | 232.327 g·mol−1 | 
| 3D model (JSmol) | |
| SMILES 
 | |
| InChI 
 | |
AAZ-A-154 is an isotryptamine derivative which acts as a 5-HT2A receptor agonist. Animal studies suggest that it produces antidepressant effects without the psychedelic action typical of drugs from this class.[1][2] In tests, AAZ-A-154 had antidepressant effects in mice without causing the head-twitch response linked to hallucinogenic effects.[3]
See also
References
- ↑ Dong C, Ly C, Dunlap LE, Vargas MV, Sun J, Hwang IW, Azinfar A, Oh WC, Wetsel WC, Olson DE, Tian L (May 2021). "Psychedelic-inspired drug discovery using an engineered biosensor". Cell. 184 (10): 2779–2792.e18. doi:10.1016/j.cell.2021.03.043. PMID 33915107.
- ↑ WO 2020176597, Olson DE, Dunlap L, Wagner FF, "N-substituted indoles and other heterocycles for treating brain disorders", published 3 September 2020, assigned to The Regents of the University of California
- ↑ Cross, Ryan (2021-09-27). "Delix raises $70 million to synthesize psychedelic-inspired drugs". cen.acs.org. Archived from the original on 2021-09-27. Retrieved 2022-01-14.
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.